Adherence to oral thromboprophylaxis in atrial fibrillation: an overview for clinicians
Europace · 31.10.2025 · 27 (11)
DOI: 10.1093/europace/euaf250 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Europace, online erschienen am 13.10.2025. Verfasst von Tatjana Potpara und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medical Faculty, University of Belgrade, Dr Subotica starijeg 8, Belgrade 11000, Serbia. Hauptthemen laut MEDLINE: Atrial Fibrillation, Anticoagulants, Medication Adherence, Stroke. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boston Scientific.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
In most patients with atrial fibrillation (AF), effective stroke prevention necessitates long-term (often lifelong) oral anticoagulant therapy (OAC). However, the effectiveness of OAC therapy in a clinical setting (i.e. outside the controlled environment of randomized clinical trials) is strongly influenced by patients’ adherence and persistence with prescribed therapy. However, suboptimal adherence to OAC remains a substantial problem in routine practice—available evidence suggests that patients do not take their OAC one out of every four days, and approximately one in three to four patients is poorly adherent to OAC. In addition, around 15% of high-risk OAC-eligible patients with AF refuse to take OAC for a variety of patient-specific reasons. Poor adherence to OAC therapy is associated with adverse clinical outcomes [such as stroke or systemic embolism, hospitalization, mortality, bleeding (particularly with vitamin K antagonist therapy)] and increased economic costs. In this overview, we summarize important aspects of the adherence to medication concept, including the definition and measurement of adherence, the determinants and prevalence of OAC non-adherence, the clinical importance of achieving and maintaining good adherence, strategies to improve adherence to OAC, and alternative treatment options for effective thromboprophylaxis in patients with AF who are non-adherent to OAC therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Faculty, University of Belgrade, Dr Subotica starijeg 8, Belgrade 11000, Serbia.
- Cardiology Clinic, University Clinical Centre of Serbia, Dr Subotica starijeg 13, Belgrade 11000, Serbia.
- 1st Department of Cardiology, Poznan University School of Medical Sciences, Poznan, Poland.
- School of Medicine and Surgery, University of Milano-Bicocca, Nephrology Clinic, Monza, Italy.
- Istituto Auxologico Italiano, IRCCS, Milan, Italy.
- Ippokrateio Hospital of Thessaloniki, Aristotle University of Thessaloniki, Thessaloniki, Greece.
ORCID-Profile: Tatjana Potpara, Bogdan G Markovic, Marek Grygier, Simonetta Genovesi, Apostolos Tzikas, Serge Boveda, Jens Erik Nielsen-Kudsk, Giuseppe Boriani, Gregory Y H Lip, A John Camm
Förderung
- Boston Scientific
Zitieren
APA
Potpara, T., Markovic, B. G., Grygier, M., Genovesi, S., Tzikas, A., Boveda, S., Nielsen-Kudsk, J. E., Boriani, G., Lip, G. Y. H., & Camm, A. J. (2025). Adherence to oral thromboprophylaxis in atrial fibrillation: an overview for clinicians. Europace, 27(11). https://doi.org/10.1093/europace/euaf250
Vancouver
Potpara T, Markovic BG, Grygier M, Genovesi S, Tzikas A, Boveda S, et al. Adherence to oral thromboprophylaxis in atrial fibrillation: an overview for clinicians. Europace. 2025;27(11). doi:10.1093/europace/euaf250
BibTeX
@article{Potpara2025,
author = {Potpara, Tatjana and Markovic, Bogdan G and Grygier, Marek and Genovesi, Simonetta and Tzikas, Apostolos and Boveda, Serge and Nielsen-Kudsk, Jens Erik and Boriani, Giuseppe and Lip, Gregory Y H and Camm, A John},
title = {Adherence to oral thromboprophylaxis in atrial fibrillation: an overview for clinicians},
journal = {Europace},
year = {2025},
volume = {27},
number = {11},
doi = {10.1093/europace/euaf250}
}
EUVIMED